Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 15, 2005

View Archived Issues

Antisoma updates pipeline progress

FDA extends Yaz oral contraceptive NDA review period

Sinovac Biotech receives government funding for pandemic vaccine development

Novartis and Ono sign Japanese agreement for rivastigmine transdermal patch

Vanda begins phase III study of iloperidone for schizophrenia

IMPACT I study of OvaRex for ovarian cancer completes enrollment

Enhanced cytotoxicity provided by new humanized anti-CD30 MAb

Preclinical profile of a novel phenyl-substituted cannabinoid presented

Therapeutic potential of Syk inhibitors from Rigel for cancer and hematological disease

CNTO-1275 modulates CLA via IL-12 in the treatment of psoriasis

LRRK2 protein identified as a potential target for the treatment of Parkinson's disease

Efficacy and minimal toxicity of pralatrexate in patients with drug-resistant T-cell lymphoma

Recent patents reveal new immunomodulators

Iplex approved for severe primary IGF-1 deficiency

New therapeutic agents for skin disorders disclosed

U.K. clearance for phase III study of CA4P in NSCLC

Xechem acquires rights to five-membered heterocyclic antisickling compound

Go-ahead for phase II study of Prochymal in Crohn's disease

Novel antiinfective agents patented

ViRexx Medical files CTA for phase I study of HepaVaxx B

New phase I studies for ALN-RSV01 for RSV

GSK to develop Vertex's VX-409 for treatment of pain

Roche files IND for Genmab collaborative antibody

GSK selects new development candidate from Cytokinetics collaboration

Radius acquires rights to Ipsen's BA-058 for osteoporosis

Phase II findings with XRP-6258 encouraging in metastatic breast cancer

SU-11248 active in patients with refractory metastatic breast cancer

AG-013736 safe when combined with docetaxel in metastatic breast cancer patients

Lapatinib assessed in phase I and II breast cancer studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...